Phoenix Children's Hospital, Inc.

Phoenix Children's Hospital, Inc., a tax-exempt nonprofit hospital organization headquartered in Phoenix, Arizona, operates as a federal grant recipient and subcontractor on pediatric research and vocational training programs, with 65% of its recent federal awards held as prime recipient or grant awardee and 35% as a sub-recipient or subcontractor. The organization holds a named subsidiary, Phoenix Children's Medical Group, and competes in the federal marketplace primarily as a research institution partner across the National Institutes of Health and other Department of Health and Human Services grant programs rather than as a federal contractor or vehicle-seated prime.

The hospital's federal footprint is concentrated in pediatric medical research and health disparities work. As a prime grant recipient, Phoenix Children's Hospital, Inc. received a $213,448 award from the National Institute for Minority Health and Health Disparities (CFDA 93.307) on July 29, 2026, to develop and test a digital health intervention addressing health disparities in underserved families of young children with spina bifida through co-design with caregiver and healthcare provider advisory boards, rapid-cycle testing with ten families, and a randomized feasibility trial running through December 31, 2030. The hospital also holds a cooperative agreement from the National Center on Birth Defects and Developmental Disabilities for the Arizona Sickle Cell Data Collection Program, awarded September 30, 2023, and running through September 29, 2028, addressing epidemiology, health utilization, and outcomes data gaps in Arizona's sickle cell disease population. As a subcontractor under Adams and Associates Inc., the hospital provides physician and nurse practitioner services to the Phoenix Job Corps Center, including outreach, admissions, career transition services, and facility construction and rehabilitation support under two federal contract sub-awards dated September 23, 2025, and July 24, 2024.

Phoenix Children's Hospital, Inc. participates as a sub-recipient on a broad portfolio of National Institutes of Health research grants led by major research universities and children's hospitals. Representative sub-grant awards include the Pediatric Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) trial under the University of Michigan (five sub-awards between January 10, 2024, and October 29, 2024), where the hospital serves as a consortia site providing case screening, enrollment, study coordination, and data collection for pediatric cardiac arrest research; the Advancing the Science of Palliative Care Research Across the Lifespan (ASCENT) Consortium under the University of Colorado (August 18, 2026); endoscopic versus shunt treatment of hydrocephalus in infants under the University of Utah (June 2, 2026); genetic sequencing and identification of inborn errors of immunity under Yale University (October 24, 2025), where the hospital's Division of Allergy and Immunology Medical Director serves as site principal investigator; and the Pacific Sickle Cell Regional Collaborative under the Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (multiple sub-awards dated September 1, 2024, October 16, 2025, and September 1, 2023). Additional sub-grant participation includes comparative effectiveness studies of cleft palate treatments, speech and language outcomes research, quality improvement studies in status epilepticus management, musculoskeletal acute care clinical trials, pediatric hemophilia care networks, influenza and COVID-19 vaccine effectiveness studies in underserved Arizona populations, and pediatric fatty liver disease research through the Translational Genomics Research Institute.

Federal customer concentration reflects the hospital's research-institution positioning. The Department of Health and Human Services dominates the award count, with HHS Indian Health Service accounting for 19 awards at $970 thousand combined potential value, HHS Health Resources and Services Administration holding 13 awards, HHS National Institute of Neurological Disorders and Stroke responsible for 7 awards, HHS National Institute of Dental and Craniofacial Research holding 6 awards, and HHS Public Health Service managing 5 awards. These five HHS sub-agencies account for 59% of all awards in the source data. Awards remain highly concentrated in medical research (23 awards coded to Medical-Managed Healthcare under the PSC taxonomy and 19 awards under Offices of Physicians NAICS), with pediatric specialization across neurology, cardiology, immunology, hematology, hepatology, and endocrinology.

Phoenix Children's Hospital, Inc. shows modest federal activity by recent volume, with two prime awards and three sub-awards placed in 2026, six prime and six sub-awards in 2025, and twelve total awards (prime and sub) in 2024. Combined potential value across all 85 awards in the source dataset stands at $1.3 million, though this figure reflects the award-database snapshot and does not capture the hospital's full federal grant revenue. Combined dollars obligated across all awards total $181.3 million, reflecting the cumulative life-of-award obligation on multi-year research grants. Two awards face ultimate completion within the next twenty-four months, presenting limited near-term recompete pressure. The hospital does not hold seats on government-wide acquisition contracts, GWACs, or enterprise IDIQs; federal work flows through grant mechanisms and direct subcontract relationships with prime vendors and research institutions.

SCI-reported federal service contract activity is minimal, capturing only one record in fiscal year 2024 in the sub-contractor capacity, representing 0.6 federal FTEs, a negligible slice of the organization's research and clinical staffing. This reflects the SCI dataset's exclusion of grant work, non-billable research coordination, and clinical service delivery outside formal service contracts above the $150,000 threshold. The hospital operates primarily as a research site and clinical partner embedded in consortial grant structures rather than as a federal contractor competing on service-contract vehicles.